Pfizer Australia and BioNTech SE today announced that the Therapeutic Goods Administration (TGA) have authorised the companies’ XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) in individuals 5 years and older.
LOXO-435 by Loxo Oncology for Solid Tumor: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug